Longitudinal assessment of chlorpyrifos exposure and self-reported neurological symptoms in adolescent pesticide applicators

• Published in: BMJ open 2014-03, Vol.4 (3), p.e004177
• Main Authors: Khan, Khalid, Ismail, Ahmed A, Abdel Rasoul, Gaafar, Bonner, Matthew R, Lasarev, Michael R, Hendy, Olfat, Al-Batanony, Manal, Crane, Alice L, Singleton, Steven T, Olson, James R, Rohlman, Diane S
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Agriculture; Biomarkers; Biomarkers - blood; Biomarkers - urine; Butyrylcholinesterase - blood; Child; Chlorpyrifos - adverse effects; Cotton; Data collection; Developing Countries; Egypt; Humans; Longitudinal Studies; Male; Nervous System Diseases - blood; Nervous System Diseases - chemically induced; Occupational and Environmental Medicine; Occupational Diseases - blood; Occupational Diseases - chemically induced; Occupational Diseases - urine; Occupational Exposure - adverse effects; Pesticides; Pesticides - adverse effects; Pyridones - urine; Questionnaires; Sample size; Self Report; Teenagers; Work; Young Adult
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2013-004177

Objectives Occupational exposure of organophosphorus pesticides, such as chlorpyrifos (CPF), in adolescents is of particular concern because of the potential vulnerability of the developing neurological system. The objectives of this study were to examine how neurological symptoms reported over the application season vary across time, whether these effects are reversible postapplication and if there are associations between CPF biomarkers and neurological symptoms in an adolescent study population. Setting The longitudinal study was conducted in two agricultural districts of Menoufia Governorate, Egypt between April 2010 and January 2011. Participants Male adolescent participants, including CPF applicators (n=57) and non-applicators (n=38), were recruited. Primary and secondary outcome measures Self-reported data for 25 neurological symptoms were collected at 32 time points over the 8-month period before, during and after the application season. Additionally, urine and blood samples were collected to measure urine trichloro-2-pyridinol (TCPy), a CPF-specific biomarker and blood cholinesterase activity. Results Applicators and non-applicators report the highest numbers of symptoms during the application season, followed by a reduction in symptoms after the application ended. Applicators reported a greater percentage of neurological symptoms, relative to baseline, than non-applicators after accounting for potential covariates. Among the applicators, cumulative TCPy was positively and significantly associated with the average percentage of symptoms (B=4.56, 95% CI 3.29 to 5.84; p